within Pharmacolibrary.Drugs.ATC.A;

model A06AH04_2
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0004166666666666667,
    adminDuration  = 600,
    adminMass      = 4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0022,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.009,
    k12             = 1.5,
    k21             = 1.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A06AH04_2</td></tr><td>route:</td><td>nasal</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Naloxone is an opioid antagonist used primarily to rapidly reverse opioid overdose. It binds to opioid receptors and can reverse and block the effects of other opioids, including respiratory depression, sedation, and hypotension. Naloxone is approved and widely used today both in emergency settings and by bystanders.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters after nasal administration in healthy adults.</p><h4>References</h4><ol><li><p>Saari, TI, et al., &amp; Dale, O (2024). Clinical Pharmacokinetics and Pharmacodynamics of Naloxone. <i>Clinical pharmacokinetics</i> 63(4) 397–422. DOI:<a href=\"https://doi.org/10.1007/s40262-024-01355-6\">10.1007/s40262-024-01355-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38485851/\">https://pubmed.ncbi.nlm.nih.gov/38485851</a></p></li><li><p>Tylleskar, I, et al., &amp; Dale, O (2017). Pharmacokinetics of a new, nasal formulation of naloxone. <i>European journal of clinical pharmacology</i> 73(5) 555–562. DOI:<a href=\"https://doi.org/10.1007/s00228-016-2191-1\">10.1007/s00228-016-2191-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28144724/\">https://pubmed.ncbi.nlm.nih.gov/28144724</a></p></li><li><p>McDonald, R, et al., &amp; Strang, J (2018). Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. <i>Addiction (Abingdon, England)</i> 113(3) 484–493. DOI:<a href=\"https://doi.org/10.1111/add.14033\">10.1111/add.14033</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29143400/\">https://pubmed.ncbi.nlm.nih.gov/29143400</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A06AH04_2;
